[go: up one dir, main page]

CL2013001297A1 - An aqueous solution comprising an ambroxol acid addition salt, in an amount of 0.1 to 7% w / v, the total content of polyalcohols selected from polyols and polyalkylene glycols of at least 20% w / v, the content Total alcohols are less than 1% w / v and the aqueous solution is free of benzoic acid. - Google Patents

An aqueous solution comprising an ambroxol acid addition salt, in an amount of 0.1 to 7% w / v, the total content of polyalcohols selected from polyols and polyalkylene glycols of at least 20% w / v, the content Total alcohols are less than 1% w / v and the aqueous solution is free of benzoic acid.

Info

Publication number
CL2013001297A1
CL2013001297A1 CL2013001297A CL2013001297A CL2013001297A1 CL 2013001297 A1 CL2013001297 A1 CL 2013001297A1 CL 2013001297 A CL2013001297 A CL 2013001297A CL 2013001297 A CL2013001297 A CL 2013001297A CL 2013001297 A1 CL2013001297 A1 CL 2013001297A1
Authority
CL
Chile
Prior art keywords
aqueous solution
content
total
ambroxol
polyols
Prior art date
Application number
CL2013001297A
Other languages
Spanish (es)
Inventor
Ginluigi Passetti
Original Assignee
Lectio Pharmaentwicklungs Und Verwertungs Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013001297(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lectio Pharmaentwicklungs Und Verwertungs Gmbh filed Critical Lectio Pharmaentwicklungs Und Verwertungs Gmbh
Publication of CL2013001297A1 publication Critical patent/CL2013001297A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
CL2013001297A 2010-12-23 2013-05-10 An aqueous solution comprising an ambroxol acid addition salt, in an amount of 0.1 to 7% w / v, the total content of polyalcohols selected from polyols and polyalkylene glycols of at least 20% w / v, the content Total alcohols are less than 1% w / v and the aqueous solution is free of benzoic acid. CL2013001297A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10196711 2010-12-23
US201061428269P 2010-12-30 2010-12-30

Publications (1)

Publication Number Publication Date
CL2013001297A1 true CL2013001297A1 (en) 2013-10-11

Family

ID=45094329

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013001297A CL2013001297A1 (en) 2010-12-23 2013-05-10 An aqueous solution comprising an ambroxol acid addition salt, in an amount of 0.1 to 7% w / v, the total content of polyalcohols selected from polyols and polyalkylene glycols of at least 20% w / v, the content Total alcohols are less than 1% w / v and the aqueous solution is free of benzoic acid.

Country Status (13)

Country Link
EP (1) EP2654719A1 (en)
JP (1) JP2014503542A (en)
KR (1) KR20130140042A (en)
CN (1) CN103269685A (en)
AR (1) AR084537A1 (en)
AU (1) AU2011347257A1 (en)
BR (1) BR112013012815A2 (en)
CA (1) CA2817453A1 (en)
CL (1) CL2013001297A1 (en)
EA (1) EA201300535A1 (en)
MX (1) MX2013005500A (en)
NZ (1) NZ609742A (en)
WO (1) WO2012085185A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102083621B1 (en) * 2013-06-13 2020-03-02 한미약품 주식회사 Oral liquid formulation having improved stability comprising ambroxol and levodropropizine
CN103462942B (en) * 2013-08-20 2016-12-28 湖南赛隆药业有限公司 A kind of suction ambroxol hydrochloride solution
CN104316482A (en) * 2014-08-15 2015-01-28 河北菲尼斯生物技术有限公司 A quality control method for ambroxol hydrochloride particles
CN105287367B (en) * 2015-10-13 2018-07-10 华润三九（南昌）药业有限公司 A kind of oral liquid of ambroxol hydrochloride and preparation method and application
CN109060473B (en) * 2018-07-27 2021-03-05 商洛学院 Preparation method of ambroxol hydrochloride impurity reference substance
CN113995721A (en) * 2020-07-27 2022-02-01 德国吉麦医疗技术有限公司 Ambroxol hydrochloride oral spray solution and preparation method thereof
CN112168782A (en) * 2020-10-26 2021-01-05 山东裕欣药业有限公司 Preparation method of respiratory system medicine oral spray
CN112168783A (en) * 2020-10-26 2021-01-05 山东裕欣药业有限公司 Oral medicine spray for respiratory system and preparation method thereof
CN114129510A (en) * 2021-12-03 2022-03-04 聊城大学 A kind of compound sulfonamide injection and preparation method thereof
CN117205149A (en) * 2023-10-08 2023-12-12 国药集团致君（深圳）坪山制药有限公司 Ambroxol hydrochloride oral solution and preparation method thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU574360B2 (en) * 1983-05-13 1988-07-07 Reichert, D. Antisnoring agent
JP2000007561A (en) * 1998-06-18 2000-01-11 Nissho Corp Ambroxol hydrochloride aqueous solution preparation
DE19933148A1 (en) 1999-07-20 2001-01-25 Boehringer Ingelheim Int Lozenge containing ambroxol
US7138133B2 (en) 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
US20030171391A1 (en) 2002-01-25 2003-09-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of chronic pain
DE10240802A1 (en) 2002-08-30 2004-04-15 W.L. Gore & Associates Gmbh IR reflective material
DE10332486A1 (en) 2003-07-16 2005-02-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of acute pain
MXPA06002715A (en) * 2003-09-09 2006-06-05 3M Innovative Properties Co Concentrated antimicrobial compositions and methods.
US20050075403A1 (en) 2003-10-02 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of inflammation in the pharynx
ITMI20032463A1 (en) 2003-12-16 2005-06-17 Advance Holdings Ltd AQUEOUS CONCENTRATED AMBROXOL SOLUTION
DE102004021992A1 (en) * 2004-05-03 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Topical preparation containing ambroxol
CN101961307B (en) * 2010-09-14 2012-07-25 武汉人福药业有限责任公司 Oral liquid for treating respiratory disease and preparation method thereof

Also Published As

Publication number Publication date
KR20130140042A (en) 2013-12-23
CN103269685A (en) 2013-08-28
EA201300535A1 (en) 2013-08-30
EP2654719A1 (en) 2013-10-30
AU2011347257A1 (en) 2013-05-23
BR112013012815A2 (en) 2016-09-13
NZ609742A (en) 2015-01-30
WO2012085185A1 (en) 2012-06-28
CA2817453A1 (en) 2012-06-28
MX2013005500A (en) 2013-09-26
AR084537A1 (en) 2013-05-22
JP2014503542A (en) 2014-02-13

Similar Documents

Publication Publication Date Title
CL2013001297A1 (en) An aqueous solution comprising an ambroxol acid addition salt, in an amount of 0.1 to 7% w / v, the total content of polyalcohols selected from polyols and polyalkylene glycols of at least 20% w / v, the content Total alcohols are less than 1% w / v and the aqueous solution is free of benzoic acid.
CL2013002599A1 (en) Composition comprising a solution of hypochlorous acid (hocl); process for preparing aqueous solution of hocl; use as an antimicrobial agent, as a cleaning agent or sterilizer; material impregnated with the composition and use to sterilize objects.
CL2013001691A1 (en) Cleaning composition comprising at least one fatty acid salt up to 50% by weight of the composition, at least one non-slip agent up to 20% of the composition, at least one dirt resistant agent up to 20% of the composition and water; cleaning method for floor surface; and team.
BRPI1007115A2 (en) "rfid transponder and method to manufacture it"
CL2013001589A1 (en) Use of an emulsion comprising 0.08% by weight or less of antimicrobial essential oil, acacia gum and water to provide an antimicrobial effect in an aqueous composition; process to improve the antimicrobial effect of an antimicrobial essential oil; and aqueous composition comprising an antimicrobial emulsion.
CL2014001941A1 (en) Process for the preparation of an aqueous solution comprising at least one alkaline earth acid carbonate; use of an aqueous solution: process for mineralization of water; and process for the production of a precipitated alkaline earth carbonate.
CL2013001104A1 (en) Pharmaceutical composition comprising a sglt2 inhibitor and an insulin; and use to treat a disease or condition such as diabetes mellitus, diabetes mellitus type 1 and 2, among others.
IT1402907B1 (en) TOPIC COMPOSITIONS TO MAINTAIN OR RESTORE THE INTEGRITY OF THE MUCOSE.
CL2015000051A1 (en) An aqueous pharmaceutical composition stabilized for long-term storage comprising etanercept and a stabilizer to prevent, inhibit or reduce the presence of subvisible particles in the composition, where the stabilizer comprises a surfactant, and where the composition is free of arginine as a stabilizer.
IT1392214B1 (en) PROCESS FOR THE PRODUCTION OF A COMPOUND OF N-BUTIRRIC ACID IN MICROCAPSULATED FORM, INTENDED FOR ANIMAL OR HUMAN POWER
CL2012000225A1 (en) Aqueous herbicidal concentrate of clopyralid (clopyralid), concentrated, low viscosity and stable to storage, comprising water and the dimethylamine salt of clopyralid in a concentration between 600-850 grams of acid equivalent per liter (gae / lt).
IT1394342B1 (en) "ENERGY SAVING IN ON-CHIP SYSTEMS"
CL2007002270A1 (en) WATER CONCENTRATE CONTAINING AT LEAST A PIRAZOLIC COMPOUND, AT LEAST A BENZOIC ACID COMPOUND AND AT LEAST A NON-IONIC SURFACE-SUBSTANCE OF TYPE S; USE OF SUCH CONCENTRATE TO COMBAT INDESEABLE VEGETABLE GROWTH; P
ECSP14013250A (en) CONCENTRATED WATERPROOF SUSPENSION INCLUDING AN ACID DODECILGUANIDINE SALT
CO6741173A2 (en) Process for leaching copper oxide by replacing sulfuric acid with a non-polluting organic leaching agent
FR2977151B1 (en) COSMETIC USE AS ANTI-TRANSPLANTING ACTIVE AN ALKALINE SILICATE
BRPI1011223A2 (en) aqueous cutting fluid and aqueous cutting agent
BR112012024339A2 (en) disintegrable buffer enclosures and their applications
BRPI1014208A2 (en) "means to receive cargo."
FR2943896B1 (en) "ROLL-ON" HAS HIGH SALICYLIC ACID CONTENT.
IT1403899B1 (en) METHOD AND SYSTEM TO CHECK THE LOSS OF RELIABILITY OF A NON-VOLATILE MEMORY
BRPI0803305C1 (en) hydromotive box
CL2007002824A1 (en) PROCEDURE TO COMBAT ANIMAL PARASITES THROUGH APPLICATION OF AN AGROCHEMICAL COMPOSITION THAT CONTAINS AT LEAST AN ACTIVE PRINCIPLE OF THE GROUP OF DIAMIDES OF FTALIC ACID INSECTICIDES; COMPOSITION IN WATERPROOF SUSPENSION CONTAINING THE PRINCIPLE
CL2013002041A1 (en) Method to control phytopathogenic fungi; use of a potassium salt of phosphoric acid because it serves to increase the effectiveness of dithianon; composition comprising potassium salt of phosphoric acid and dithianon.
ES2545508T3 (en) Use of benzoic acid or a salt thereof to reduce urinary tract disorders in ruminants